Zangari, Maurizio <br/><br/>
Alkaline phosphatase variation during carfilzomib treatment is associated with best response in multiple myeloma patients.  [electronic resource] 

 -  European journal of haematology  Jun 2011 
 - 484-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article 
<br/><br/><label>ISSN: </label>1600-0609 
<br/><br/><label>Standard No.: </label>10.1111/j.1600-0609.2011.01602.x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Alkaline Phosphatase--blood<br/>Antineoplastic Agents--therapeutic use<br/>Boronic Acids--therapeutic use<br/>Bortezomib<br/>Drug Resistance, Neoplasm<br/>Female<br/>Humans<br/>Male<br/>Middle Aged<br/>Multiple Myeloma--drug therapy<br/>Oligopeptides--therapeutic use<br/>Osteogenesis--drug effects<br/>Protease Inhibitors--therapeutic use<br/>Proteasome Inhibitors<br/>Pyrazines--therapeutic use<br/>Retrospective Studies<br/>Treatment Outcome